The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Much Is The Ribonucleic Acid (RNA) Therapy Clinical Trials Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?
The market size for ribonucleic acid (rna) therapy clinical trials has experienced steady growth in recent years. It is anticipated to increase from $2.7 billion in 2025 to $2.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.8%. The expansion observed in the historical period was shaped by various factors, including limited rna-based therapeutic options, the significant cost of early-stage clinical trials, difficulties in obtaining regulatory approval, insufficient understanding of rna therapies, and a prevailing reliance on conventional treatment methods.
The ribonucleic acid (rna) therapy clinical trials market is anticipated to experience consistent expansion over the upcoming years, reaching a valuation of $3.4 billion by 2030, driven by a compound annual growth rate (CAGR) of 4.7%. This anticipated growth during the forecast timeframe is primarily due to several factors, including ongoing advancements in rna delivery technologies, a rise in funding dedicated to rare disease and anticancer research, heightened collaboration between biotechnology and pharmaceutical firms, the increasing embrace of personalized medicine strategies, and the broadening of global clinical trial networks. Key trends expected within this period involve an escalating number of rna therapy clinical trials spanning various therapeutic domains, an amplified emphasis on rare disease and anticancer rna therapeutics, the expansion of trials for mrna vaccines and self-amplifying rna therapies, the integration of CRISPR and rna editing-based therapy trials, and the incorporation of sophisticated delivery platforms alongside oligonucleotide conjugates.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25896&type=smp
What Key Drivers Are Influencing The Growth Of The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
The escalating challenge presented by infectious diseases is anticipated to fuel the expansion of the ribonucleic acid (RNA) therapy clinical trials market moving forward. These diseases are ailments caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that invade the body, multiply, and compromise well-being. The growth in infectious diseases is substantially influenced by the increase in global travel, which allows for the swift dissemination of pathogens across different regions and populations. Ribonucleic acid (RNA) therapy clinical trials assist in addressing infectious diseases by facilitating the creation and assessment of specific treatments that can rapidly adapt to newly emerging pathogens. For instance, a report released in April 2025 by the Minnesota Department of Health, a US-based state agency, highlighted that in 2024, the share of HIV cases among males aged 35 to 39 climbed from 10% in 2023 to 17%. Thus, the intensifying impact of infectious diseases is propelling the growth of the ribonucleic acid (RNA) therapy clinical trials market.
What Major Segment Divisions Exist Within The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
The ribonucleic acid (rna) therapy clinical trials market covered in this report is segmented –
1) By Modality: Ribonucleic Acid (RNA) Interference, Antisense Therapy, Messenger Ribonucleic Acid (RNA), Oligonucleotide, Non-Antisense, Non-Ribonucleic Acid Interference (RNAi)
2) By Clinical Trials Phase: Phase I, Phase II, Phase III, Phase IV
3) By Therapeutic Areas: Rare Diseases, Anti-Infective, Anticancer, Neurological, Alimentary Or Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas
Subsegments:
1) By Ribonucleic Acid (RNA) Interference: Small Interfering RNA (siRNA) Therapy Trials, MicroRNA (miRNA)-Based Therapy Trials, Short Hairpin RNA (shRNA) Therapy Trials, Dicer Substrate RNA Therapy Trials
2) By Antisense Therapy: Gapmer Antisense Oligonucleotide Trials, Steric Blocking Antisense Trials, Splice-Switching Antisense Oligonucleotide Trials, Antisense Oligonucleotide-Conjugated Delivery Trials
3) By Messenger Ribonucleic Acid (RNA): mRNA-Based Vaccines Trials, Self-Amplifying mRNA (saRNA) Therapy Trials, Non-Replicating mRNA Therapy Trials, Circular mRNA Therapy Trials
4) By Oligonucleotide: Phosphorothioate Oligonucleotide Trials, Peptide Nucleic Acid (PNA) Trials, Locked Nucleic Acid (LNA) Trials, Morpholino Oligonucleotide Trials
5) By Non-Antisense: RNA Aptamer Therapy Trials, Guide RNA (gRNA)-Mediated CRISPR Trials, RNA Editing Therapy Trials, RNA Scaffolding Or Regulatory RNA Therapy Trials
6) By Non-Ribonucleic Acid Interference (RNAi): Ribozymes Therapy Trials, RNA Decoys Or Sponge RNA Trials, Long Non-Coding RNA (lncRNA) Therapy Trials, Small Activating RNA (saRNA) Therapy Trials
How Are Trends Shaping The Direction Of The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
Leading companies in the ribonucleic acid (RNA) therapy clinical trials market are concentrating on developing innovative solutions, such as RNA-based antisense oligonucleotide therapy clinical trials, with the aim of targeting specific genetic sequences, modulating gene expression, and providing highly precise treatments for genetic and rare diseases. An RNA-based antisense oligonucleotide therapy clinical trial specifically refers to a study that investigates the use of short synthetic RNA strands to bind particular messenger RNA targets, seeking to modulate gene expression and treat genetic disorders. For example, in December 2024, Sepul Bio, a biotechnology company located in France, commenced the LUNA Phase 2b clinical trial to assess ultevursen, an RNA-based antisense oligonucleotide therapy designed to address mutations in exon 13 of the USH2A gene, which are responsible for retinitis pigmentosa (RP) and Usher syndrome type 2a. This two-year, double-masked, randomized, sham-controlled study plans to enroll 81 adults and children aged eight and above across numerous global sites. The therapy is intended for individuals with RP or non-syndromic RP resulting from exon 13 mutations in USH2A, which can be confirmed through genetic testing. The LUNA trial proceeds after encouraging results from earlier Phase 1/2 studies, where ultevursen demonstrated benefits in visual acuity, retinal sensitivity, and retinal structure.
Which Companies Are Leading Innovation In The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
Major companies operating in the ribonucleic acid (rna) therapy clinical trials market are Pfizer Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., BioNTech SE, Biogen Inc., Daiichi Sankyo Company Limited, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Cartesian Therapeutics Inc., CureVac N.V., Orna Therapeutics Inc., Silence Therapeutics plc, ETHRIS GmbH, ProQR Therapeutics N.V., Lexeo Therapeutics Inc., Avidity Biosciences Inc., Aro Biotherapeutics Company, Wave Life Sciences Ltd.
Read the full ribonucleic acid (rna) therapy clinical trials market report here:
Which Region Is Expected To Register The Fastest Growth In The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?
North America was the largest region in the ribonucleic acid (RNA) therapy clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna) therapy clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Ribonucleic Acid (RNA) Therapy Clinical Trials Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25896&type=smp
Browse Through More Reports Similar to the Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market 2026, By The Business Research Company
Ribose Nucleic Acid Rna Based Therapeutics Market Report 2026
Nucleic Acid Based Gene Therapy Market Report 2026
Ribonucleic Acid Rna Sequencing Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model